Berger M, Biasin E, Saglio F, Fagioli F
Paediatric Onco-Haematology and Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Turin, Italy.
Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S101-5. doi: 10.1038/bmt.2008.294.
First-line treatment of GVHD is based on steroids and produces sustained responses in 50-80% of patients with acute GVHD (aGVHD) and 40-50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.
移植物抗宿主病（GVHD）的一线治疗以类固醇为基础，根据初始疾病严重程度，50%-80%的急性移植物抗宿主病（aGVHD）患者和40%-50%的慢性移植物抗宿主病（cGVHD）患者会产生持续反应。对于无反应的儿童，则采用多种药物联合进行二线治疗，但目前可用的药物并未提高这些高危人群的生存率。在这篇小型综述中，我们将重点关注治疗儿童患者GVHD的新药物。
